Ignyta (RXDX) Appoints Valerie Harding As Senior Vice President, Chemistry, Manufacturing, And Controls

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Valerie Harding, Ph.D., has been appointed to the newly-created role of Senior Vice President, Chemistry, Manufacturing, and Controls.

"We are fortunate to add Val to our executive team at this point in the growth of our company," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "Val's rich experience in pharmaceutical drug development and formulation, cultivated over more than 25 years at Pfizer, will be indispensable to us as we advance our commercialization plans for entrectinib and continue the development of the rest of our pipeline for the benefit of cancer patients."

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.